TKI resistance related genes in LUAD predict patient prognosis and tumor immune microenvironment with LHX2 as a hub gene.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), is a leading cause of cancer-related mortality. Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), improves survival, but acquired resistance remains a major clinical challenge.

Methods

Transcriptomic profiles of osimertinib-sensitive and -resistant EGFR-mutant cell lines were analyzed to identify resistance mechanisms. Resistance-associated genes were used to develop a Cox proportional hazards (CoxPH) prognostic model based on The Cancer Genome Atlas (TCGA) data. Immune context and tumor mutational burden (TMB) were compared between risk groups. Core gene expression was validated by reverse transcription quantitative polymerase chain re

SUBMITTER: Huang R 

PROVIDER: S-EPMC12627286 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature